Floatz logo

Empagliflozin

Cystic Fibrosis-Related Diabetes

University of MinnesotaSmall moleculePhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Cystic Fibrosis-Related Diabetes cohort.

Asset / SponsorPhaseRating
Glargine Insulin
University of Minnesota
Phase 3BB
Semaglutide
University of Minnesota
Phase 2/3B
Insulin Detemir [Rdna Origin]
Nationwide Children's Hospital
Phase 2/3CCC
Metformin
University of Kansas Medical Center
Phase 2CCC
GLUCOSE, ANHYDROUS
Children's Hospital of Philadelphia
Early Phase 1CCC
Dorzagliatin
University of Pennsylvania
Phase 1CC
REPAGLINIDE
Arbelaez, Ana Maria
N/AD

Same molecule, other indications

Empagliflozin is also rated in:

metabolic dysfunction-associated steatotic liver diseaseDormant
BBB
Indicative ·
76 / 100
View asset →
Hypoglycemic AgentsDormant
BBB
Indicative ·
75 / 100
View asset →
prediabetes syndromeDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →